Business Wire

O-RAN Alliance Conducts First Global Plugfest to Foster Adoption of Open and Interoperable 5G Radio Access Networks

Share

The O-RAN Alliance successfully conducted its first worldwide plugfest and proof of concept to demonstrate the functionality as well as the multi-vendor interoperability of network equipment that complies with the recently published O1, A1, and Open Fronthaul interface specifications.

“O-RAN’s first global plugfest showcases the power of the community to document and develop truly open interface specifications with the potential to accelerate new 5G advanced services that will be multi-operator, multi-vendor, and create opportunities for the entire ecosystem,” said Andre Fuetsch, Chairman of the O-RAN Alliance and Chief Technology Officer of AT&T. “These live demonstrations represent yet another step toward the realization of O-RAN compliant 5G RAN solutions that should soon become part of the product offerings of both mainstream and niche vendors.”

ASIA

Hosted by China Mobile, the plugfest Asian Session was held in the China Mobile International Information Port, an Open Test and Integration Center, with physical attendance well over 200 attendees from over 70 companies, plus on-line attendance of over 70 participants. Representatives from global operators including British Telecom, China Telecom, China Unicom, NTT DOCOMO, Orange, Reliance Jio, Telecom Italia Mobile and an operator from North America have actively participated in this event. The plugfest tested and integrated multi-vendor solutions that comply with the O-RAN Open Fronthaul interface and exercised decoupling different hardware technologies from the RAN software:

  1. Cloud-based small cell running on virtualization technology was demonstrated by CertusNet, Lenovo, ChengDu NTS and Inventec. It features a VM-based O-CU and containerized O-DU cohosted on the same x86 processor plus accelerator platform.
  2. Multi-vendor interoperability with 5G commercial products was demonstrated by NTT DOCOMO with Fujitsu and NEC.
  3. A low power configuration of cloud base station running on Yocto OS and container technology was demonstrated by Altran, ArrayComm, WindRiver, Baicells and CIG. It features the open architecture baseband signal processing based on ARM processor plus accelerator computing platform.
  4. Soft base station with O-RAN compliant open fronthaul interface, but without virtualization, was demonstrated by Radisys, Foxconn (Taiwan), QCT and Intel. It leverages open source software including the O-RAN Open Source Community’s OFH Lib, and BBDev based Accelerator Abstraction Layer SDK API.
  5. The interworking of the O-RAN open fronthaul interface was demonstrated on technology provided by FHK (Shenzen) and Viavi, which performs comprehensive tests based on the test specification by O-RAN with O-RU and UE emulator in a multiple-UE test environment.

The plugfest held in the NTT DOCOMO R&D Center presented multi-vendor interoperability between CU/O-DU and O-RU using the O-RAN Open Fronthaul interface and multi-vendor interoperability between eNB and gNB using the O-RAN X2 interface. The functionality has been successfully demonstrated by NTT DOCOMO, Fujitsu, NEC, and Nokia. NTT DOCOMO has already started 5G pre-commercial service with the presented products. An Open Test and Integration Center is planned to be established in Japan.

NORTH AMERICA

The plugfest and proof-of-concept conducted within an Open Test and Integration Center candidate in North America, 5G COSMOS, which consists of vendor and university labs in the NYC metro area, was hosted by AT&T and focused primarily on the validation of the O1 and A1 interfaces:

  1. Physical Network Function (PNF) Plug and Play, a 3GPP-aligned O1 use case that provides a means for service providers to collaborate with equipment vendors to have PNFs discovered by Service Management Orchestration (SMO) via a PNF registration handler, was demonstrated by Nokia, CommScope and Ericsson. Remote SMO functions were also demonstrated with connections to labs in France and Germany.
  2. Bulk Performance Management Data Collection was demonstrated by Ericsson and Nokia.
  3. O1 interface functionality for Configuration, Performance, and Fault Management of multi-vendor equipment via a vendor-agnostic SMO was demonstrated by Altiostar, CommScope, and Samsung.
  4. A1 interface functionality to optimize PCI/RSI for a large-scale RAN simulator using a closed loop automation framework was demonstrated by IBM, Tech Mahindra, Wipro and highstreet technologies.
  5. Convergence of the Open Fronthaul Management Plane specification with O1 interface was demonstrated by Samsung.

“The O-RAN Alliance has been continuously expanding its influence in the industry since its inception. It is really amazing to see such a symbolic milestone achieved just 10 months since its release of the first specification in MWC Barcelona this year,” said Zhengmao Li, EVP of China Mobile. “The successful holding of the plugfest event globally with deep contribution from over 30 partners represents a consolidated step towards a full disaggregated O-RAN compliant 5G network.”

Dr. Hiroshi Nakamura, EVP and CTO, NTT DOCOMO commented, "We believe wide adoption of O-RAN compliant products will enable more agile, flexible and cost-effective network construction, and welcome the testing and integration efforts of O-RAN standards that are being carried out across the globe. NTT DOCOMO will continue to lead O-RAN Alliance activities and expand its 5G network, and will accelerate the co-creation of 5G services and markets with vertical industry partners."

O-RAN Industry Briefing at MWC 2020

For a comprehensive update on O-RAN activities, including significant developments in Europe, the O-RAN community will come together for the O-RAN Industry Briefing event at MWC Barcelona 2020. Representatives from O-RAN operator and vendor member organizations will discuss and share views on the important steps towards realizing O-RAN compliant commercial solutions. O-RAN Alliance is looking forward to meeting you on Feb 25, 2020, 9:30-10:30 am at the Deutsche Telekom Booth, Hall 3, Booth 3M31.

About O-RAN Alliance

O-RAN Alliance is a world-wide community of more than 130 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, O-RAN Alliance’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN standards will enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN-compliant mobile networks will at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, O-RAN Alliance publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.

For more information please visit www.o-ran.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

O-RAN Alliance PR Contact

Zbynek Dalecky
pr@o-ran.org
O-RAN Alliance e.V.
Buschkauler Weg 27
53347 Alfter/Germany

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye